Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial | Zendy

Éric Pujade-Lauraine | Zendy; Felix Hilpert | Zendy; B. Weber | Zendy; Alexander Reuß | Zendy; Andrés Poveda | Zendy; Gunnar B. Kristensen | Zendy; Roberto Sorio | Zendy; Ignace Vergote | Zendy; Petronella O. Witteveen | Zendy; Aristotelis Bamias | Zendy; Deolinda Pereira | Zendy; Pauline Wimberger | Zendy; Ana Oaknin | Zendy; Mansoor Raza Mirza | Zendy; Philippe Follana | Zendy; David T. Bollag | Zendy; Isabelle RayCoquard | Zendy

Open Access

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Author(s) -

Éric Pujade-Lauraine,

Felix Hilpert,

B. Weber,

Alexander Reuß,

Andrés Poveda,

Gunnar B. Kristensen,

Roberto Sorio,

Ignace Vergote,

Petronella O. Witteveen,

Aristotelis Bamias,

Deolinda Pereira,

Pauline Wimberger,

Ana Oaknin,

Mansoor Raza Mirza,

Philippe Follana,

David T. Bollag,

Isabelle RayCoquard

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.51.4489

Subject(s) - medicine , bevacizumab , chemotherapy , hazard ratio , topotecan , progression free survival , surgery , clinical endpoint , ovarian cancer , gastroenterology , oncology , cancer , randomized controlled trial , confidence interval

In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research